Business

Know the Business

IFF is one of four firms that effectively decide what the world's food, drinks, laundry detergent, and perfume smell and taste like. The business sells a tiny but irreplaceable 1-5% of a consumer product's cost that is locked in by decades of R&D collaboration, regulatory filings, and specification-level approvals. The pre-pandemic IFF was a 20%+ EBITDA-margin compounder; the post-2021 IFF is the same great duopolistic core (Taste, Scent, Health & Biosciences) buried under the balance-sheet wreckage of the 2021 DuPont N&B merger — which is what the market is being asked to look through in 2026.

**Bottom line.** The economic engine is intact — 19-26% segment EBITDA margins, double-digit return on tangible assets, and a real moat in flavors/scents/enzymes. What is *not* intact is capital allocation history: two major deals (Frutarom 2018, DuPont N&B 2021) destroyed over **$5B of goodwill** through 2025 impairments. The reader's job is to price the ongoing business, not the acquisition hangover.

1. How This Business Actually Works

IFF sells a 1-5% ingredient that decides whether a $4 yogurt or a $120 perfume is a repeat purchase. That asymmetry — tiny cost share, enormous influence on the finished product's identity — is the entire source of pricing power.

Revenue engine

The revenue model has four pillars, each with different economics:

Taste (~23% of 2025 sales, 19% EBITDA margin) — flavor compounds for beverages, snacks, dairy. Each win is typically a single SKU at a single customer; switching is painful because the formula IS the product's taste.
Scent (~23%, 21% margin) — fragrance compounds for luxury perfumes (high-margin, creative brief-driven) and consumer laundry/personal care (volume, technical performance).
Health & Biosciences (~21%, 26% margin) — biotech-derived enzymes, probiotics, cultures. Highest margin, hardest to replicate, partly overlapping with Novonesis (the Novozymes-Chr. Hansen merger).
Food Ingredients (~30%, 13% margin) — the commoditized piece: texturants, soy/pea protein, emulsifiers. Management has announced intent to divest, which would lift consolidated margins by ~300-400 bps.

Cost structure and bargaining power

Cost of sales is ~64% of revenue. Raw materials include ~20,000 SKUs sourced globally — half natural (essential oils, citrus, vanilla, cocoa), half synthetic. IFF has limited bargaining power up the chain on a single raw material year, but two structural offsets matter: (1) raw materials rarely exceed 5% of a customer's finished product cost, so IFF can pass through, lagged by 1-2 quarters; (2) the company is vertically integrated on many key fragrance ingredients, which it also sells to competitors — the Scent segment is both a compound producer and an ingredient wholesaler.

Downstream, the buyer side is concentrated but not dangerously so: the top 25 customers (Unilever, P&G, Nestle, PepsiCo, L'Oreal, Coca-Cola, etc.) account for ~32% of sales, no single customer is 10%. The critical contractual reality is the "core list" — once you are on a multinational's supplier core list for a category, you get first look at every new product brief in that category. Being dropped is a slow process (years), not an event.

What actually drives incremental profit

Operating leverage is moderate because gross margin is structural, not a function of capacity utilization spikes. The three levers that matter:

Mix shift toward fine fragrance and H&B — each point of mix into these segments is worth ~30 bps of consolidated EBITDA margin.
Pricing/raw material spread — when raw materials deflate and IFF holds price (as in H2 2024 / 2025), margins expand 150-300 bps in a year.
Productivity from plant consolidation — IFF runs ~170 manufacturing sites post-mergers; management is targeting ~$300M of productivity by 2027.

2. The Playing Field

The flavors & fragrances industry is a global oligopoly with a three-decade history of acquiring its way to scale. Four firms — Givaudan, DSM-Firmenich, IFF, and Symrise — control roughly 60-65% of the $30B F&F market. IFF sits #2 in flavors, #2 in fragrances, and #1 or #2 in enzymes/cultures depending on sub-category.

No Results

**Read the table this way.** Givaudan and Novonesis trade at premium multiples because they are pure-play specialists with higher margins. IFF trades below both on forward P/E despite similar *core* business economics — the discount is the leverage + integration risk from DuPont N&B, not the underlying segments.

Relative positioning

IFF is the only player that is simultaneously #2 in flavors, #2 in fragrances, #1-2 in enzymes, AND large in commodity food ingredients. That breadth was the 2018-2021 thesis ("Nutrition & Biosciences") and is now the disassembly project. Management has said the ongoing business should look more like Givaudan + H&B — which, if executed, closes ~500 bps of the margin gap to Givaudan.

Where IFF's moat is real — and where it isn't

Real moat: fine fragrance creation (relationships with the ~500 working master perfumers globally), enzymes and cultures (patent + know-how-protected, regulated), flavor formulations on customer core lists.
Weak or absent moat: plant-based protein, soy lecithin, commodity emulsifiers — the Food Ingredients segment. This is why the 2025 impairment hit Food Ingredients ($1.15B) and 2023 hit the former Nourish ($2.6B).

3. Is This Business Cyclical?

F&F is the most defensive corner of specialty chemicals — but not recession-proof, and the 2022-2023 destocking cycle proved it.

Two separate things happen in this chart, and the reader has to untangle them:

The step-ups in 2019 and 2021 are the Frutarom and DuPont N&B acquisitions, not organic growth.
The margin collapse in 2022-2023 is two shocks stacked: raw material/energy inflation (pricing caught up in H2 2023) and a historic customer destocking cycle (CPG customers ran inventory down through 2023).

Where the cycle actually hits

Fine fragrance (~10% of sales): highly discretionary. Down 15-25% in deep recessions (2009, 2020 initial weeks).
Consumer fragrance, flavors, enzymes (~70% of sales): volumes tied to grocery and household staple consumption. Single-digit volume swings in downturns.
Food Ingredients commodity tail (~15%): behaves like an agrochemical — raw material volatility drives margin, not demand.

The 2022-2023 destocking was an inventory cycle, not a demand cycle — pantry consumption of IFF-ingredient products barely moved, but CPG customers drew down inventory hard. That matters because it means the 2023 sales drop was not a bearish signal about the category's long-term growth — it was a one-time working-capital reset. IFF's working capital swung by ~$1.5B across 2022-2024, which is what the cash flow statement shows.

**The cycle IFF is actually exposed to is the customer CPG re-order cycle, not consumer demand.** When P&G, Unilever, and Nestle run inventory tight, IFF gets whipsawed 12-18 months ahead of what consumers actually buy.

4. The Metrics That Actually Matter

Forget headline EPS — it is distorted by goodwill impairment and divestiture gains/losses for at least three more years. These five metrics explain value creation in this business:

No Results

Deleveraging is the dominant variable

The post-DuPont-N&B debt peak was $11.4B in 2021. By end-2025, IFF has retired ~$5.4B of debt, roughly half through Pharma Solutions divestiture proceeds ($2.7B) and half through operating cash flow. Every $1B of further debt reduction is worth roughly $40M of annual interest savings at current rates, which is real after-tax EPS.

5. What I'd Tell a Young Analyst

This is not a flavors and fragrances company to value in 2026 — it is a deleveraging, divestiture, and margin-repair story wearing a F&F company as a coat. The right question is not "what is IFF worth as a business?" It is "what is the end-state business worth, and what is the probability management gets there?"

Three things to do first:

Ignore GAAP EPS entirely for this cycle. Model segment EBITDA by segment, subtract real corporate overhead, subtract real D&A (not amortization of Frutarom/DuPont intangibles), subtract real interest. That is the earning power. It is around $1.5-1.8B post-Food-Ingredients-divestiture.
Benchmark against Givaudan, not against the S&P. Givaudan trades at ~20x EBITDA because it is a disciplined operator in the same category. If IFF can get to 21-22% consolidated EBITDA margins (within reach after divesting Food Ingredients) with under 2x leverage, the multiple gap will close to within ~3 turns. That is the re-rating trade.
Watch three specific signals. Core-list retention on the top 25 customers (disclosed qualitatively in the 10-K); Food Ingredients sale price and timing (management has guided to divestiture); and price/mix contribution in H&B (the highest-margin segment — if this stalls, the thesis is in trouble).

The thing to avoid: falling in love with the "global oligopoly" narrative and ignoring that IFF's capital allocation track record since 2018 has been categorically worse than every peer. Frutarom was overpaid. DuPont N&B was a stretch deal at a cyclical peak. The underlying business is superb. The board and two successive CEOs have been mediocre stewards of it. A young analyst's discipline is to price both.